Top

Published in:

01-02-2011 | Brief Report

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

Authors: Pamela J. Goodwin, Vuk Stambolic, Julie Lemieux, Bingshu E. Chen, Wendy R. Parulekar, Karen A. Gelmon, Dawn L. Hershman, Timothy J. Hobday, Jennifer A. Ligibel, Ingrid A. Mayer, Kathleen I. Pritchard, Timothy J. Whelan, Priya Rastogi, Lois E. Shepherd

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792CrossRefPubMed

Viani GA, Alfonso SL, STafano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2 positive early breast cancer: a meta-analysis of published randomized studies. BMC Cancer; 7:153CrossRefPubMedPubMedCentral

Bedard PL, de Azambuja E, Cardoso F (2009) Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 9:148–162CrossRefPubMed

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305CrossRefPubMedPubMedCentral

Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258CrossRefPubMed

Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E (2009) Sulphonylureas and cancer: a case–control study. Acta Diabetol 46:279–284CrossRefPubMed

Libby G, Donnelly LA, Donnan PT, Alessi Dr, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625CrossRefPubMedPubMedCentral

Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed

10.

Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304–1308CrossRefPubMedPubMedCentral

11.

Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236–238CrossRefPubMed

12.

Pollak MN, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C et al (2006) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol 24(Suppl 18S):(Abstr 524)

13.

Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20:1128–1143CrossRefPubMed

14.

Goodwin PJ, Pritchard KI, Ennis M, Koo J, Hood N (2009) Long-term effects of fasting insulin in early stage breast cancer patients. Eur J Cancer Suppl 7:308 (abstr P-5160)

15.

Belfiore A, Frasca F (2008) IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:381–406CrossRefPubMed

16.

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302CrossRefPubMedPubMedCentral

17.

Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501–505CrossRefPubMed

18.

Vigneri P, Frasca F, Sciacca, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Rel Cancer 16:1103–1123CrossRef

19.

Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T et al (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 3:1077–1083CrossRef

20.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174CrossRefPubMedPubMedCentral

21.

Hawley SA, Gadalla AE, Olsen GS, Hardie DG (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425CrossRefPubMed

22.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273CrossRefPubMed

23.

Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 1:369–375CrossRef

24.

Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18CrossRefPubMedPubMedCentral

25.

Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE et al (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909–915CrossRefPubMed

26.

Hirsch HA, Iliopoulos D, Tsichlis PN (2009) Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511CrossRefPubMedPubMedCentral

27.

Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8:88–96CrossRefPubMed

28.

Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA (2009) The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20:592–595CrossRefPubMed

29.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lilnd SE et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031–2040CrossRefPubMed

30.

Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ (2009) Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat 114:387–389CrossRefPubMed

31.

Phoenix KN, Vumbaca F, Claffey KP (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113:101–111CrossRefPubMed

Title: Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents
Authors: Pamela J. Goodwin
Vuk Stambolic
Julie Lemieux
Bingshu E. Chen
Wendy R. Parulekar
Karen A. Gelmon
Dawn L. Hershman
Timothy J. Hobday
Jennifer A. Ligibel
Ingrid A. Mayer
Kathleen I. Pritchard
Timothy J. Whelan
Priya Rastogi
Lois E. Shepherd
Publication date: 01-02-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1224-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

A small number of subjects do not always indicate that they are minor variants data for inclusion in a pooled analysis

Role of ferritin alterations in human breast cancer cells

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Effects of breast cancer surgery and surgical side effects on body image over time

Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia

Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians

Keynote webinar | Spotlight on antibody–drug conjugates in cancer